Related Experiment Video

Updated: Jun 20, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Pharmacological targeting of CDK9 in cardiac hypertrophy

Vladimír Krystof1, Ivo Chamrád, Radek Jorda

  • 1Faculty of Science, Laboratory of Growth Regulators, Palacký University & Institute of Experimental Botany AS CR, Slechtitelů 11, Olomouc 783 71, Czech Republic. vladimir.krystof@upol.cz

Medicinal Research Reviews
|September 17, 2009
PubMed

Insights

Cyclin-dependent kinase 9 (CDK9) drives cardiac hypertrophy, leading to heart failure. Inhibiting CDK9 shows promise for developing new cardiac hypertrophy drugs.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Pharmacology

Background:

  • Cardiac hypertrophy is an adaptive response to increased workload, but chronic or abnormal stimuli can lead to heart failure.
  • Cellular growth in cardiac hypertrophy involves increased transcription and translation.
  • Cyclin-dependent kinases (CDKs) regulate transcription, with CDK9 playing a key role.

Purpose of the Study:

  • To investigate the role of CDK9 in cardiac hypertrophy.
  • To explore the potential of CDK9 inhibitors as a therapeutic strategy for cardiac hypertrophy.

Main Methods:

  • Analysis of molecular mechanisms linking CDK9 to cardiac myocyte enlargement.
  • Review of existing small-molecule CDK9 inhibitors developed for oncology.
  • Consideration of CDK9 crystal structure for selective inhibitor design.

Main Results:

  • CDK9 activation leads to cardiac myocyte enlargement and heart failure predisposition.
  • Small-molecule CDK9 inhibitors are available, with potential for optimization.
  • CDK9's crystal structure facilitates the development of selective inhibitors.

Conclusions:

  • CDK9 is a critical regulator of cardiac hypertrophy.
  • Targeting CDK9 with small-molecule inhibitors represents a novel therapeutic approach for cardiac hypertrophy and heart failure.

More Related Videos

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity08:00

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Published on: July 10, 2019

Isolation, Culture, and Functional Characterization of Adult Mouse Cardiomyoctyes12:49

Isolation, Culture, and Functional Characterization of Adult Mouse Cardiomyoctyes

Published on: September 24, 2013

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.